24 Participants Needed

Theta Burst Stimulation for Depression and Autism

(RETSORE-RCT Trial)

MP
JC
Overseen ByJennifer Combs, Masters
Age: < 65
Sex: Any
Trial Phase: Academic
Sponsor: Children's Hospital Medical Center, Cincinnati
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

You don't have to stop taking your current medications, but you should try to keep them stable during the study. However, if you are currently using anticonvulsant, barbiturate, lithium, or benzodiazepine medications, you cannot participate in the trial.

What data supports the effectiveness of the treatment Theta Burst Stimulation for depression and autism?

Research shows that Theta Burst Stimulation (TBS), a type of transcranial magnetic stimulation (TMS), can be effective for major depressive disorder (MDD). Some studies suggest that different TBS protocols, like intermittent TBS (iTBS) and continuous TBS (cTBS), have shown promise in treating depression, although results can vary.12345

Is theta burst stimulation (TBS) safe for humans?

Research shows that theta burst stimulation (TBS) is generally safe and well-tolerated in humans, with most side effects being mild. However, there is a small risk of seizures, so it should be used with caution.56789

How is Theta Burst Stimulation (TBS) different from other treatments for depression and autism?

Theta Burst Stimulation (TBS) is a unique form of transcranial magnetic stimulation (TMS) that uses rapid bursts of magnetic pulses to modulate brain activity, potentially offering a faster and more targeted approach compared to traditional repetitive TMS (rTMS). It is being explored for its effectiveness in treating depression and autism, with some studies suggesting it may enhance the effects of existing treatments like medication and psychotherapy.12345

What is the purpose of this trial?

Evaluate the efficacy of accelerated theta burst stimulation (aTBS) in reducing depressive symptoms in autism spectrum disorder (ASD)

Research Team

RE

Rana Elmaghraby, MD

Principal Investigator

Cincinnati Childrens Hospital Medical Center

Eligibility Criteria

This trial is for individuals with Autism Spectrum Disorder (ASD) who are also experiencing hard-to-treat depression. Participants should be diagnosed with both conditions and have not found relief from standard treatments.

Inclusion Criteria

Fluent in English and able to volunteer in the informed consent process and provide spontaneous narrative description of key elements, risks, and benefits of the study
Full-scale intelligence quotient ≥ 70
I am between 13 and 26 years old.
See 5 more

Exclusion Criteria

Actively suicidal (i.e., suicidal ideation with plan and intent) or deemed at high risk for suicide
I have previously undergone rTMS treatment.
For female subjects of childbearing potential, a positive urine pregnancy test
See 4 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2 weeks
1 visit (in-person)

Treatment

Participants receive either active or sham accelerated theta burst stimulation (aTBS) targeting the left dorsolateral prefrontal cortex, 5 sessions per day for 5 days

1 week
5 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, with assessments at 2-week, 6-week, and 12-week intervals

12 weeks
3 visits (in-person)

Open-label extension (optional)

Participants in the sham group who do not show a significant treatment response by the 12-week follow-up are eligible for active, open-label treatment

Treatment Details

Interventions

  • Theta Burst Stimulation
Trial Overview The study is testing the effectiveness of a technique called accelerated theta burst stimulation (aTBS), which uses magnetic fields to stimulate certain areas of the brain, in reducing symptoms of depression in people with ASD.
Participant Groups
2Treatment groups
Active Control
Placebo Group
Group I: Active TBS TreatmentActive Control1 Intervention
Active aTBS targeting the left dorsolateral prefrontal cortex, 5 sessions per day for 5 days.
Group II: Sham controlledPlacebo Group1 Intervention
Sham aTBS targeting the left dorsolateral prefrontal cortex, 5 sessions per day for 5 days. If participants in the sham group do not show a significant treatment response by the 12-week follow-up - defined as a 50% reduction from baseline on the HDRS- they will then become eligible for and offered active, open-label treatment.

Theta Burst Stimulation is already approved in United States for the following indications:

🇺🇸
Approved in United States as Theta Burst Stimulation for:
  • Major Depressive Disorder

Find a Clinic Near You

Who Is Running the Clinical Trial?

Children's Hospital Medical Center, Cincinnati

Lead Sponsor

Trials
844
Recruited
6,566,000+

Findings from Research

In a randomized-controlled trial involving 32 patients with major depression, bilateral theta burst stimulation (TBS) to the dorsolateral prefrontal cortex showed a significant increase in treatment response compared to sham stimulation, with 9 responders in the TBS group versus 4 in the sham group.
The study also indicated a trend towards higher remission rates in the TBS group as measured by the Beck Depression Inventory, suggesting that TBS may enhance the effectiveness of ongoing medication and psychotherapy in treating major depression.
Treatment of major depression with bilateral theta burst stimulation: a randomized controlled pilot trial.Plewnia, C., Pasqualetti, P., Große, S., et al.[2018]
In a study involving 36 participants, it was found that the intensity of transcranial magnetic stimulation (TMS) significantly affects the plasticity response in the primary motor cortex, with higher intensities (150% of resting motor threshold) yielding greater depression effects from continuous theta burst stimulation (cTBS).
For intermittent theta burst stimulation (iTBS), the most effective probing intensity was at 110% of resting motor threshold, indicating that different intensities are crucial for accurately assessing neuroplasticity responses.
Probing changes in corticospinal excitability following theta burst stimulation of the human primary motor cortex.Goldsworthy, MR., Vallence, AM., Hodyl, NA., et al.[2017]
Continuous theta burst stimulation (cTBS) was found to be safe and well-tolerated in patients with major depressive disorder (MDD) or bipolar depression (BD), with no significant differences in adverse events compared to sham treatment.
However, the meta-analysis of three randomized controlled trials involving 78 participants showed no significant improvement in depression scores or response rates with cTBS compared to sham, indicating that cTBS may not provide a therapeutic advantage for treating major depressive episodes.
Adjunctive continuous theta burst stimulation for major depressive disorder or bipolar depression: A meta-analysis of randomized controlled studies.Cai, DB., Qin, XD., Qin, ZJ., et al.[2023]

References

Treatment of major depression with bilateral theta burst stimulation: a randomized controlled pilot trial. [2018]
Probing changes in corticospinal excitability following theta burst stimulation of the human primary motor cortex. [2017]
Adjunctive continuous theta burst stimulation for major depressive disorder or bipolar depression: A meta-analysis of randomized controlled studies. [2023]
Dose-dependence of changes in cortical protein expression induced with repeated transcranial magnetic theta-burst stimulation in the rat. [2016]
Prolonged intermittent theta burst stimulation in the treatment of major depressive disorder: a case series. [2022]
Safety and tolerability of theta burst stimulation vs. single and paired pulse transcranial magnetic stimulation: a comparative study of 165 pediatric subjects. [2020]
Safety of theta burst transcranial magnetic stimulation: a systematic review of the literature. [2022]
The acute effects of accelerated repetitive Transcranial Magnetic Stimulation on suicide risk in unipolar depression: preliminary results. [2022]
Safety, tolerability and preliminary evidence for antidepressant efficacy of theta-burst transcranial magnetic stimulation in patients with major depression. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security